Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema

Gian Marco Tosi, Antonio Vitale, Donato Rigante, Jurgen Sota, Giacomo Emmi, Giuseppe Lopalco, Silvana Guerriero, Florenzo Iannone, Lorenzo Vannozzi, Alice Bitossi, Bruno Frediani, Luca Cantarini, Claudia Fabiani

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Objective To assess the efficacy of anti-tumour necrosis factor (TNF)-α agents in the treatment of refractory uveitic macular oedema (UME). Methods Patients with refractory UME treated with TNF-α blockers were retrospectively enrolled. Central macular thickness (CMT) was assessed at optical coherence tomography (OCT) at the start of TNF-α inhibition, after 3 and 12 months, and at the last follow-up visit. Results Thirty-six patients (56 eyes with UME) were enrolled. The mean follow-up period was 29.9±40.8 (4-184) months. A statistically significant decrease was observed in the frequency of UME (p<0.0001) and in the mean CMT values (p<0.0001) during the study period. Best corrected visual acuity improved in 35 eyes (62.5%), remained stable in 12 eyes (21.4%), reduced in 9 eyes (16.1%). The mean corticosteroid dosage significantly decreased during the study period (p=0.016). Conclusion TNF-α inhibitors represent a useful treatment in patients with severe or resistant UME.
Lingua originaleEnglish
pagine (da-a)621-625
Numero di pagine5
RivistaClinical and Experimental Rheumatology
Stato di pubblicazionePubblicato - 2020


  • Adalimumab
  • Certolizumab
  • Golimumab
  • Infliximab
  • Uveitis


Entra nei temi di ricerca di 'Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema'. Insieme formano una fingerprint unica.

Cita questo